Quest PharmaTech Inc. (CVE:QPT – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 4000 shares changing hands. The stock had previously closed at C$0.03.
Quest PharmaTech Trading Down 20.0%
The stock has a market capitalization of C$3.38 million, a PE ratio of 0.68 and a beta of -0.75. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The stock’s 50 day moving average price is C$0.02 and its 200-day moving average price is C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Articles
- Five stocks we like better than Quest PharmaTech
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
- Disney Is Opening the Door to Netflix—and Changing the Streaming Playbook
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
